Want to see EVMN full AI Analyst Report?
Top Page
Evommune, Inc.
(NYSE:EVMN)
Select Model
Select Model
Rating:47Neutral
Price Target:
$11.00
▼(-59.93% Downside)
Action:Reiterated
Date:07/30/26
The score is held back primarily by persistent large losses and accelerating cash burn despite strong revenue growth and a materially improved balance sheet. Technically, the stock is weak with price well below key moving averages. Corporate events are mixed (new migraine Phase 2b start offset by a Phase 2b failure and program halt in urticaria), while valuation is difficult to support given the negative P/E and no dividend.
Positive Factors
Revenue Growth
Sustained revenue growth over 2023–2025 indicates expanding commercial traction or successful early-stage partnerships. A rising top line provides a durable base to scale R&D and clinical programs, reducing reliance solely on financing if the trend continues.
Negative Factors
Negative Cash Generation
Deep and worsening negative operating and free cash flow indicate persistent burn from R&D and trials. Over multiple quarters this increases financing needs, elevates dilution risk and constrains discretionary investment, pressuring long-term execution if revenue scaling lags.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained revenue growth over 2023–2025 indicates expanding commercial traction or successful early-stage partnerships. A rising top line provides a durable base to scale R&D and clinical programs, reducing reliance solely on financing if the trend continues.
Read all positive factors
Evommune, Inc. (EVMN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$398.00M
Dividend YieldN/A
Average Volume (3M)935.27K
Price to Earnings (P/E)―
Beta (1Y)-0.25
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees48
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,018,370
10 Day Avg. Volume412,591
30 Day Avg. Volume935,274
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)2.63
Price to Sales (P/S)41.51
P/FCF Ratio-7.04
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue25.33
Enterprise Value/Gross Profit27.31
Enterprise Value/Ebitda-3.39
Forecast
1Y Price Target
$37.60Price Target Upside36.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Evommune, Inc. Business Overview & Revenue Model
Company Description
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical de...
How the Company Makes Money
null...
Evommune, Inc. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 10.00M | 13.00M | 7.00M | 5.00M |
| Gross Profit | 9.28M | 13.00M | 5.71M | 4.00M |
| EBITDA | -74.62M | -67.48M | -65.49M | -32.99M |
| Net Income | -75.99M | -68.87M | -66.81M | -34.05M |
Balance Sheet | ||||
| Total Assets | 322.45M | 224.95M | 76.06M | 82.25M |
| Cash, Cash Equivalents and Short-Term Investments | 211.46M | 149.20M | 72.04M | 79.08M |
| Total Debt | 9.11M | 2.06M | 193.31M | 150.63M |
| Total Liabilities | 17.90M | 19.38M | 220.29M | 159.96M |
| Stockholders Equity | 304.56M | 205.57M | -144.24M | -77.71M |
Cash Flow | ||||
| Free Cash Flow | -80.36M | -76.68M | -58.28M | -30.09M |
| Operating Cash Flow | -80.05M | -76.44M | -58.20M | -29.97M |
| Investing Cash Flow | -214.17M | -115.31M | -3.99M | -48.43M |
| Financing Cash Flow | 338.03M | 220.76M | 49.42M | 63.75M |
Evommune, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.46B | -2.83 | -53.31% | ― | 213.96% | 25.74% | |
57 Neutral | $567.86M | -3.22 | -42.57% | ― | 80.00% | 25.18% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | $164.57M | -2.03 | -36.55% | ― | -67.73% | -11.57% | |
47 Neutral | $398.00M | -4.71 | -195.15% | ― | ― | ― | |
47 Neutral | $402.84M | -5.32 | -9999.00% | ― | -1.26% | -23.97% | |
41 Neutral | $481.35M | -2.70 | -106.22% | ― | -9.42% | -67.60% |
* General Sector Average
EVMN
Evommune, Inc.
11.35
-8.88
-43.90%
ALT
Altimmune
2.98
-0.63
-17.45%
ARCT
Arcturus Therapeutics
5.92
-6.38
-51.87%
OCGN
Ocugen
1.26
0.27
26.89%
VIR
Vir Biotechnology
8.90
3.87
76.94%
VALN
Valneva
5.09
-2.13
-29.54%
Evommune, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Evommune Launches Phase 2b Trial for EVO756 Migraine Drug
Positive
Jul 30, 2026
On July 30, 2026, Evommune announced that it had dosed the first patient in a global Phase 2b clinical trial of its oral MRGPRX2 inhibitor, EVO756, for prophylactic treatment of refractory migraine. The randomized, double-blind, placebo-controlled...
Business Operations and StrategyProduct-Related Announcements
Evommune Halts EVO756 Urticaria Trial, Pipeline Advances
Negative
Jun 29, 2026
On June 29, 2026, Evommune reported top-line results from a randomized, double-blind, placebo-controlled Phase 2b trial of oral MRGPRX2 antagonist EVO756 in 160 adults with moderate-to-severe, antihistamine-refractory chronic spontaneous urticaria...
Executive/Board ChangesShareholder Meetings
Evommune Stockholders Reelect Directors and Ratify Auditor
Positive
Jun 2, 2026
On June 2, 2026, Evommune, Inc. held its 2026 Annual Meeting of Stockholders, where a quorum was present and shareholders elected directors Luis Peña and Eugene Bauer, M.D., to serve on the board until the 2029 annual meeting or until success...
Business Operations and StrategyFinancial Disclosures
Evommune Highlights Q1 Results and Advancing Inflammation Pipeline
Positive
May 7, 2026
Evommune, Inc., a clinical-stage biotech specializing in therapies for chronic inflammatory diseases such as atopic dermatitis, chronic urticaria and related conditions, reported first quarter 2026 financial results and detailed progress across it...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.